Article Text
Commentary
Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable
Statistics from Altmetric.com
Footnotes
Contributors SD-B and YY participated in writing the paper, drafted the word and approved the final version to be published.
Competing interests SD-B has received research grants from Roche, Janssen and Schering-Plough/Merck, and consultancy honoraria from Abbott, Abbvie, Bristol-Myers Squibb, Glaxo Smith Kline, HEVA, Janssen, Schering-Plough/Merck and Public Health Expertise. YY has received travel grants, lecture fees and consulting honoraria from Abbott/Abbvie, Bristol-Myers Squibb Gilead, Roche, Schering-Plough/Merck, Tibotec and ViiV Healthcare.
Provenance and peer review Commissioned; internally peer reviewed.